Custom service
Yeast Cell based VLP Production
Self-assembling particles at fermentation scale, without baculovirus infrastructure.
Yeast sits between bacterial and mammalian systems: it self-assembles particles cheaply and at scale, with the option of secretion, and it adds folding assistance and disulfide formation that bacteria lack. The licensed HPV vaccines were made in yeast, which is the clearest evidence that the system can carry a particle-based product all the way to regulatory acceptance.
Pichia pastoris is the default host, driven by a methanol-inducible or constitutive promoter, with particles assembled intracellularly or secreted depending on the construct. Saccharomyces cerevisiae is used where its specific glycosylation or GRAS status matters. Expression is optimised for induction timing and medium composition, because particle yield and monomer subunit yield peak differently, and the harvest window matters as much as in any other VLP system.
Hypermannosylation is the system's known weakness, and it is handled rather than ignored. Glycoengineered Pichia strains with humanised glycans are available where the particle's surface must not carry yeast-type glycans, and deglycosylation strategies are applied where the glycan interferes with assembly or antigenicity. Each batch is profiled, so the glycan question is answered with data rather than with reassurance.
Yeast VLP production suits high-yield capsid particles for immunisation and diagnostics, programmes that need fermentation-scale economics, and products whose regulatory story benefits from a yeast precedent.
It is not the route for enveloped particles requiring mammalian trafficking, or for surface proteins whose antigenicity collapses under yeast glycosylation — unless a glycoengineered strain is used, which is decided during design rather than after the first batch.
Batches ship with TEM morphology and count, N-glycan profile, protein composition by mass spectrometry, antigenicity where a readout exists, and endotoxin. Where a glycoengineered strain is used, the glycan profile is compared against the standard strain to document the difference.
Service Highlights
- Fermentation scale. Particles produced at the yields and costs of yeast fermentation, without baculovirus infrastructure.
- Two assembly modes. Intracellular assembly for robust production, secretion for simplified purification.
- Glycoengineered strains. Pichia with humanised N-glycosylation pathways available where yeast-type glycans would compromise the product.
- Licensed-system precedent. The same class of system produced approved HPV vaccines, which matters for regulatory conversations.
- Disulfide-capable folding. Oxidising secretory pathway supports epitopes that require disulfide bonds.
- Particle-level QC. EM morphology, particle count, glycan profiling and antigenicity measured on every batch.
How the work runs
Host and construct design
Pichia or Saccharomyces chosen against glycan requirements; promoters, secretion signals and assembly strategy defined.
Expression optimisation
Induction conditions, medium and harvest time screened for particle yield.
Preparative fermentation
Shaker flask to fermenter scale under the optimised condition.
Purification
Cell disruption or harvest of secreted particles, clarification, nuclease treatment, and particle purification by SEC or gradient.
Glycan and particle QC
N-glycan profiling, TEM morphology and count, protein composition by LC-MS.
Antigenicity and release
Binding to conformational antibodies or ligands measured on the final particle.
Specifications & timeline
- Hosts
- Komagataella (Pichia) pastoris, Saccharomyces cerevisiae; glycoengineered strains available
- VLP types
- Non-enveloped capsids and custom assemblies
- Scale
- 1–50 L fermentation
- QC
- TEM, LC-MS, N-glycan profile, antigenicity, endotoxin
- Timeline
- 6–10 weeks per construct
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.